×

Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

  • US 10,383,930 B2
  • Filed: 08/10/2018
  • Issued: 08/20/2019
  • Est. Priority Date: 08/05/2015
  • Status: Active Grant
First Claim
Patent Images

1. A method of eliciting an immune response in a patient who has prostate cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells, which present a peptide consisting of the amino acid sequence of SLFHPEDTGQV (SEQ ID NO:

  • 49),wherein the peptide is in a complex with an MHC molecule,wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell,wherein the activated T cells are expanded in vitro in the presence of an anti-CD28 antibody and IL-12.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×